Here are four highlights:
1. The new data on the TIF procedure with the EsophyX device will include a meta-analysis poster presentation titled “Efficacy of Transoral Incisionless Fundoplication for Gastroesophageal Reflux Disease.”
2. The meta-analysis reviewed ten randomized, controlled and prospective cohort clinical trials to evaluate the overall efficacy of the TIF procedure for treating patients with GERD.
3. The original EsophyX device was cleared by the FDA in 2007. The company launched the third generation EsophyX device, the EsophyX Z, in 2015.
4. Based in Redmond, Wash., EndoGastric Solutions is a medical device company focused on developing and commercializing incisionless surgical technology for the treatment of GERD.
More articles on GI & endoscopy:
White House acknowledges AGA’s microbiome initiatives: 5 key notes
5 most read GI/endoscopy stories: May 9 – May 13
Exact Sciences completes 40k Cologuard tests, but net loss totals $47.5M: 6 key notes on Q1 2016
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
